raloxifene

Raloxifene (LY139481) is a selective estrogen receptor modulator that exhibits both estrogen agonist and antagonist activities at certain sites, with antiviral activity against viruses like Ebola, influenza, and HCV, useful for studying viral infections.

Raloxifene hydrochloride (LY156758 hydrochloride) is a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene is an LRH-1 antagonist with an IC50 of 3.1 μM.

Raloxifene 4'-glucuronide, a primary metabolite of Raloxifene.

Raloxifene 6,4'-Bis-β-D-glucuronide, a metabolite of Raloxifene, acts as a selective antagonist of the estrogen receptor used for osteoporosis prevention.

Raloxifene 6-glucuronide, a primary metabolite of Raloxifene, is mediated predominantly by UGT1A1 and UGT1A8.

Raloxifene Bismethyl Ether hydrochloride, a metabolite of Raloxifene, is an estrogen receptor inactive compound with both hydroxyl groups absent.

Raloxifene Bismethyl Ether, a Raloxifene metabolite, is an estrogen receptor inactive compound that lacks both hydroxyl groups.

Raloxifene N-Oxide is an oxidative degradation product of Raloxifene.

Raloxifene alkene (Compound 101) is a significant serum cholesterol-clearing agent. It exhibits notable antiproliferative activity against breast cancer cells. In an ovariectomized rat model, Raloxifene alkene effectively reduces serum cholesterol levels without significantly increasing uterine weight or the number of eosinophils in stromal cells. This compound is applicable for research into postmenopausal syndrome, particularly osteoporosis, estrogen-dependent breast cancer, and uterine cancer.

Raloxifene-D4 hydrochloride is the deuterated form of Raloxifene hydrochloride (T1549). Raloxifene (Keoxifene) is a selective estrogen receptor modulator (SERM) of the benzothiophene class. It exhibits estrogen agonistic effects on bone and blood lipids, while acting as an estrogen antagonist on breast and uterine tissues. This compound is utilized in research related to breast cancer and osteoporosis.

Raloxifene impurity 8 is an impurity of Raloxifene.

Raloxifene impurity 4 (Raloxifene impurity B) is an impurity of Raloxifene.

Raloxifene impurity 2 is a contaminant of Raloxifene.

Raloxifene impurity 6 is a byproduct of Raloxifene.

Raloxifene impurity 3 is an impurity of Raloxifene.

Raloxifene impurity 1 is an impurity of Raloxifene.

Raloxifene impurity 5 is a contaminant associated with Raloxifene.

Raloxifene 4'-glucuronide lithium is a pharmaceutical impurity.

4'-Raloxifene-β-D-glucopyranoside is a metabolite of Raloxifene. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist.

6-Raloxifene-β-D-glucopyranoside is a benzothiophene glucuronidated at the 6' position. It is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss, resorption, and lowering lipid

4-tert-Butyldimethylsilyl-6-hydroxy Raloxifene is a compound resulting from the reaction of Raloxifene with tertbutyldimethylsilyl chloride.

Methyl Raloxifene 4'-(2,3,4-Tri-O-acetyl-β-D-glycopyranuronate) is a derivative of Raloxifene 4'-glucuronide, engineered to mimic the structure and function of the parent compound.

Compound 7, or Raloxifene 6-Monomethyl Ether, is a derivative of Raloxifene that effectively inhibits estrogen receptor α. It also displays the inhibitory effects on MCF-7 cells, with an IC50 of 250 nM and a pIC50 of 6.6.